Skip to content

The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in “Bath Salts”

L. Watterson, L. Hood, Kaveish Sewalia, S. Tomek, Stephanie L. Yahn, C. T. Johnson, S. Wegner, B. Blough, J. Marusich, M. Olive

Journal of Addiction Research & Therapy December 1, 2012 DOI: 10.4172/2155-6105.s9-002 via Semantic Scholar

Summary

AI-generated from the abstract

Methylone, a synthetic cathinone sold as 'bath salts', acts as a reinforcer in rats, with higher doses leading to greater drug-seeking behavior. Short daily access to methylone produced more robust self-administration than previously seen with MDMA. However, extended daily access did not lead to increased intake or heightened reinforcing effects, unlike cocaine or methamphetamine. Methylone also showed a dose-dependent but non-significant trend toward lowering brain reward thresholds. These findings suggest methylone's addiction potential may be similar to or greater than MDMA, but its abuse and compulsive use potential appears lower than that of typical psychostimulants.

Study at a glance

Characteristics Preclinical experimental study Peer reviewed
Population Rats
Intervention Methylone
Dose 0.05, 0.1, 0.2, and 0.5 mg/kg/infusion
Duration 2 hr/day short access sessions and 6 hr/day long access sessions
Keywords Medicine Psychology
Citations 71
Key finding Methylone functions as a reinforcer in rats dose-dependently, but extended access does not escalate intake, suggesting lower abuse potential than prototypical psychostimulants.

Abstract

Methylone is a member of the designer drug class known as synthetic cathinones which have become increasingly popular drugs of abuse in recent years. Commonly referred to as “bath salts”, these amphetamine-like compounds are sold as “legal” alternatives to illicit drugs such as cocaine, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Following their dramatic rise in popularity along with numerous reports of toxicity and death, several of these drugs were classified as Schedule I drugs in the United States in 2012. Despite these bans, these drugs and other new structurally similar analogues continue to be abused. Currently, however, it is unknown whether these compounds possess the potential for compulsive use and addiction. The present study sought to determine the relative abuse liability of methylone by employing intravenous self-administration (IVSA) and intracranial self-stimulation (ICSS) paradigms in rats. We demonstrate that methylone (0.05, 0.1, 0.2, and 0.5 mg/kg/infusion) dose-dependently functions as a reinforcer, and that there is a significant positive relationship between methylone dose and reinforcer efficacy. Furthermore, responding during short access sessions (ShA, 2 hr/day) appeared more robust than previous IVSA studies with MDMA. However, unlike previous findings with abused stimulants such as cocaine or methamphetamine, long access sessions (LgA, 6 hr/day) did not lead to escalated drug intake or increased reinforcer efficacy. Finally, methylone produced a dose-dependent, but statistically non-significant, trend towards reductions in ICSS thresholds. Together these results reveal that methylone may possess an addiction potential similar to or greater than MDMA, yet patterns of self-administration and effects on brain reward function suggest that this drug may have a lower potential for abuse and compulsive use than prototypical psychostimulants.

Comments

No comments yet.

Log in to comment